Tandem Diabetes Care, Inc. $TNDM Position Cut by Aberdeen Group plc

Aberdeen Group plc reduced its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 72.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 121,948 shares of the medical device company’s stock after selling 319,790 shares during the period. Aberdeen Group plc’s holdings in Tandem Diabetes Care were worth $1,989,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of TNDM. Maryland State Retirement & Pension System bought a new position in shares of Tandem Diabetes Care in the third quarter valued at approximately $249,000. Fulcrum Asset Management LLP raised its holdings in Tandem Diabetes Care by 1,463.6% during the third quarter. Fulcrum Asset Management LLP now owns 4,378 shares of the medical device company’s stock worth $73,000 after purchasing an additional 4,098 shares in the last quarter. Provenance Wealth Advisors LLC bought a new stake in Tandem Diabetes Care during the third quarter worth approximately $158,000. Summit Global Investments lifted its position in Tandem Diabetes Care by 13.9% in the third quarter. Summit Global Investments now owns 24,753 shares of the medical device company’s stock worth $404,000 after purchasing an additional 3,017 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in Tandem Diabetes Care by 31.3% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 34,400 shares of the medical device company’s stock worth $561,000 after purchasing an additional 8,200 shares during the period.

Tandem Diabetes Care Stock Performance

NASDAQ TNDM opened at $17.46 on Friday. Tandem Diabetes Care, Inc. has a 1 year low of $12.26 and a 1 year high of $29.65. The business’s fifty day moving average is $17.25 and its two-hundred day moving average is $18.78. The company has a quick ratio of 2.65, a current ratio of 3.20 and a debt-to-equity ratio of 4.47.

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical device company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.15. The business had revenue of $283.69 million during the quarter, compared to analyst estimates of $265.85 million. Tandem Diabetes Care had a negative return on equity of 35.61% and a negative net margin of 4.58%. The company’s revenue was up 13.8% compared to the same quarter last year. During the same period last year, the company posted ($0.31) EPS. On average, analysts forecast that Tandem Diabetes Care, Inc. will post -0.61 EPS for the current fiscal year.

Insider Activity

In other news, Director Christopher J. Twomey sold 1,700 shares of the company’s stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total transaction of $32,555.00. Following the completion of the sale, the director directly owned 24,434 shares of the company’s stock, valued at $467,911.10. This represents a 6.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on TNDM. UBS Group raised Tandem Diabetes Care from a “neutral” rating to a “buy” rating in a research note on Wednesday. Canaccord Genuity Group set a $40.00 price objective on Tandem Diabetes Care in a report on Friday, August 7th. Citigroup cut their price objective on Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, September 30th. William Blair started coverage on Tandem Diabetes Care in a research note on Friday, August 21st. They set an “outperform” rating for the company. Finally, Wells Fargo & Company lowered their target price on Tandem Diabetes Care from $27.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, November 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $27.39.

Get Our Latest Stock Report on TNDM

About Tandem Diabetes Care

(Free Report)

Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.

Featured Articles

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report).

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.